Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Acquisitions (2016 - 2024)

Ligand Pharmaceuticals (LGNDZ) has disclosed Acquisitions for 8 consecutive years, with -$92.0 million as the latest value for Q4 2024.

  • Quarterly Acquisitions changed N/A to -$92.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$92.0 million through Dec 2024, changed N/A year-over-year, with the annual reading at $10.4 million for FY2023, N/A changed from the prior year.
  • Acquisitions hit -$92.0 million in Q4 2024 for Ligand Pharmaceuticals, down from $378.0 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $378.0 million in Q4 2020 to a low of -$92.0 million in Q4 2024.